WORLD
UK to allow entry to travellers vaccinated with Covishield from October 4
Indians will still have to take tests on arrival and quarantine for ten days.
BUSINESS
Explainer: Why India is relaxing export restrictions on COVID-19 vaccines
For one, India has to keep its commitment under a global initiative called COVAX. The other reason, as an expert says, is that if India doesn't ease export restrictions, it will benefit China, which is making deeper inroads into low and middle-income countries with vaccine diplomacy.
BUSINESS
UK may review its new COVID travel policy for India: Sources
"Everybody knows that it is identical, it is been proven. We have submitted the data to EMA and the UK MHRA. They are reviewing it, I have had a personal consultation with the regulator there, they are going to get back to us shortly," said Adar Poonawalla, CEO of SII.
BUSINESS
India to resume exports of surplus COVID-19 vaccines from October under Vaccine Maitri programme
Union health minister Mansukh Mandaviya said more than 30 crore doses will be produced in October and more than 100 crores in the coming quarter.
BUSINESS
Adar Poonawalla-backed Mylab acquires point-of-care testing provider Sanskritech
Sanskritech's Swayam is a portable diagnostic and telemedicine point-of-care system that can be used to create a small lab anywhere. This will allow people to test for a wide range of diseases within a few minutes
BUSINESS
Biocon, SII deal to extend to exploring partnership in biologics, mRNA vaccines
Biocon and SII are exploring development and commercialisation of SII's biologic portfolio, considering manufacture of raw materials for vaccines and biologics, and plan to develop and make drugs and vaccines based on mRNA platform.
BUSINESS
Sputnik Light single-dose vaccine launch in India may get delayed
An expert panel of the Central Drugs Standard Control Organisation asks company to conduct Phase-3 immune-bridging clinical trials on Indian population. Dr Reddy's spokesperson declines to say when the trial will start.
BUSINESS
Delayed launch of Glumetza: Lupin settles case for $248 million
The law suits in US courts alleged that the 2012 settlement of patent litigation regarding Glumetza delayed the availability of generic alternatives, causing consumers to pay higher prices for the drug.
BUSINESS
DCGI led panel formed to frame new New Drugs, Cosmetics and Medical Devices Bill starts process
"The committee has decided to conduct a consultative meeting with the Consumer Associations scheduled to held on September 19 between 2 - 4 pm," the notification released by Somani said.
BUSINESS
No new side effects found in COVID-19 antiviral Favipiravir: Glenmark
Glenmark said the time for fever resolution was four days while time for clinical cure was seven days.
BUSINESS
Poonawalla-backed Wellness Forever to file for Rs 1,600-crore IPO
The retail pharmacy chain will file its draft documents by end-September.
BUSINESS
Laurus Labs joins hands with Unitaid, CHAI to develop and commercialise pediatric HIV drug combo
Laurus will be provided with a financial incentive for a portion of their development and commercialisation costs. CHAI will work closely with Laurus Labs to provide technical and regulatory support to enable accelerated generic development and regulatory submission of the medication.
BUSINESS
IPO-bound PharmEasy parent appoints five independent directors, to hire over 200 engineers
“The fresh appointments bring a great amount of cognitive diversity to the board, with luminaries from the world of public service, technology, pharma, medical fraternity, and the consumer sector," the company said in a statement.
BUSINESS
Advanced Enzymes says its enzymes, probiotics aid faster recovery in long-COVID patients
The products were launched on Amazon under brand names ‘ImmunoSEB’ and ‘Biome ULTRA’ in the US and Indian markets.
BUSINESS
NABL a voluntary accreditation body, has no regulatory powers: N Venkateswaran, CEO
"Checking of compliance to the regulatory requirements falls under the purview of the respective applicable regulator," Venkateswaran says. NABL has been drawing flak, especially for issuing accreditation for labs that are not complying with regulatory practices.
BUSINESS
Indian pharmaceutical market grow at 17.7% in August
India’s $1.8 trillion pharmaceuticals market is showing signs of returning to normalcy as sales of Non-COVID products, which account for 63 percent of the market, is rising strongly while growth of some pandemic-related products like vitamins has tapered.
BUSINESS
Govt forms panel headed by DCGI to frame new Drugs, Cosmetics, Medical Devices bill
“The committee shall undertake pre legislative consultations and examine the present Act, previously framed Drugs and Cosmetics Bills and submit a draft document for a de-novo Drugs, Cosmetics and Medical Devices bill,” the notification said.
BUSINESS
Cipla seeks price hike for certain respiratory medications, writes to NPPA
Cipla spokesperson confirmed the development, and said the products impacted are a "small subset" of the overall basket of respiratory products.
BUSINESS
Panacea Biotec rolls out first batch of Sputnik V second jab
The second jab of Sputnik V is being manufactured at the Panacea Biotec’s facility in Himachal Pradesh
BUSINESS
Goldman Sachs-backed Aragen Life Sciences on expansion mode, evaluating select acquisition opportunities
With revenue of Rs 1,200 crore in the financial year 2021, Aragen provides outsourcing services for drug discovery, clinical trials, and manufacturing to over 450 clients globally, including many large biotech and pharmaceutical companies.
BUSINESS
Hetero to launch Tocilizumab, gets DCGI’s emergency use nod
While Hetero didn't announce the price of the drug, but the biosimilar version is expected to be cheaper than the branded Tocilizumab which is priced at Rs 40,600 per single injection. A COVID-19 patient would typically require about two injections.
BUSINESS
Govt utilised 23.6% of budgeted Rs 35,000 crore for COVID-19 vaccines till July
The government has spent Rs 9,229.31 crore between March and July to procure 124 crore doses from three manufacturers.
BUSINESS
SII puts Indian demand for COVID-19 vaccine above exports
"Once the supply-demand situation eases in India, we will think about exports," said one of the people, requesting anonymity.
BUSINESS
New list of essential medicines: 39 new drugs added, 16 dropped
Most of the new drugs added to the list were anti-cancer like Azacitidine and Fludarabine antiretroviral such as Dolutegravir, Darunavir+Ritonavir, new generation TB medications such as Bedaquiline and Delamanid, anti-allergy Montelukast, anti diabetes drugs like Teneligliptin and Insulin Glargine.
